COL4A3杂合子的表型谱
在Geisinger MyCode/DiscovEHR队列174,418名参与者中,识别出403名COL4A3可能致病杂合子,按1:5倾向性匹配非杂合子。COL4A3杂合子血尿、eGFR下降、白蛋白尿和肾衰竭风险显著增加,但双侧感音神经性听力损失无显著差异。胶原域甘氨酸错义变异表型较蛋白截断变异更重。
要点
- COL4A3杂合子血尿、eGFR下降、白蛋白尿和肾衰竭风险显著增加。
- Gly695Arg变异者血尿OR 9.50、肾衰竭OR 7.02,PTV者分别为1.64和3.44。
- 不足三分之一患者完成白蛋白尿筛查,不足三分之一使用RAAS抑制剂。
核心结论
- COL4A3杂合子所致ADAS表型谱广泛,且表型严重程度因基因型而异。
研究设计与样本
- 基于Geisinger MyCode/DiscovEHR队列174,418名参与者的全外显子测序数据,识别403名COL4A3可能致病杂合子,按1:5倾向性评分匹配非杂合子。
主要发现
- COL4A3杂合子血尿、eGFR下降、白蛋白尿和肾衰竭风险显著增加(P < 0.05),双侧感音神经性听力损失无显著差异(P = 0.9)。
- Gly695Arg组(n = 161)vs PTV组(n = 119):试纸血尿OR 9.50(95%CI 6.32, 14.28)vs OR 1.64(95%CI 1.03, 2.59),肾衰竭OR 7.02(95%CI 3.48, 14.16)vs OR 3.44(95%CI 1.28, 9.22)。
- 不足三分之一患者完成白蛋白尿筛查,不足三分之一使用肾素-血管紧张素-醛固酮系统抑制剂。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The penetrance and phenotypic spectrum of autosomal dominant Alport Syndrome (ADAS), affecting 1 in 106, remains understudied. METHODS: Using data from 174,418 participants in the Geisinger MyCode/DiscovEHR study, an unselected health system-based cohort with whole exome sequencing, we identified 403 participants who were heterozygous for likely pathogenic COL4A3 variants. Phenotypic data was evaluated using International Classification of Diseases (ICD) codes, laboratory data, and chart review. To evaluate the phenotypic spectrum of genetically-determined ADAS, we matched COL4A3 heterozygotes 1:5 to nonheterozygotes using propensity scores by demographics, hypertension, diabetes, and nephrolithiasis. RESULTS: COL4A3 heterozygotes were at significantly increased risks of hematuria, decreased estimated glomerular filtration rate (eGFR), albuminuria, and kidney failure (P < 0.05 for all comparisons) but not bilateral sensorineural hearing loss (P = 0.9). Phenotypic severity was more severe for collagenous domain glycine missense variants than protein truncating variants (PTVs). For example, patients with Gly695Arg (n = 161) had markedly increased risk of dipstick hematuria (odds ratio [OR] 9.50; 95% confidence interval [CI]: 6.32, 14.28) and kidney failure (OR 7.02; 95% CI: 3.48, 14.16) whereas those with PTVs (n = 119) had moderately increased risks of dipstick hematuria (OR 1.64; 95% CI: 1.03, 2.59) and kidney failure (OR 3.44; 95% CI: 1.28, 9.22). Less than a third of patients had albuminuria screening completed, and fewer than 1 of 3 were taking inhibitors of the renin-angiotensin-aldosterone system. CONCLUSION: This study demonstrates a wide spectrum of phenotypic severity in ADAS due to COL4A3 with phenotypic variability by genotype. Future studies are needed to evaluate the impact of earlier diagnosis, appropriate evaluation, and treatment of ADAS.
引用
- Solanki KV, Hu Y, Moore BS, et al. The Phenotypic Spectrum of COL4A3 Heterozygotes. Kidney Int Rep. 2023. PMID: 37849993. doi:10.1016/j.ekir.2023.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。